CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $121.46M, lower than 95% of all stocks globally
- PositionGross margin is -0.1%, lower than 95% of its Biotechnology peers (median 67.1%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
173.10BKRW121.46M · vs all stocks (USD)
Revenue (TTM)
2.08BKRW1.46M · vs all stocks (USD)
52-Week Change
-46.47%vs all stocks
Market Capitalization
173.10BKRW121.46M · vs all stocks (USD)
Enterprise Value
151.95BKRW106.62M · vs all stocks (USD)
Price to Sales (TTM)
78.85xvs Biotechnology peers
Price to Book (MRQ)
8.41xvs Biotechnology peers
Enterprise to Revenue
73.12xvs Biotechnology peers
Enterprise to EBITDA
-17.54xvs Biotechnology peers
Gross Margin
-0.12%vs Biotechnology peers
Operating Margin
-398.95%vs Biotechnology peers
Return on Assets (TTM)
-17.06%vs Biotechnology peers
Return on Equity (TTM)
-35.08%vs Biotechnology peers
Revenue (TTM)
2.08BKRW1.46M · vs all stocks (USD)
Revenue per Share (TTM)
162.06KRWUpdated Jul 15, 2026Quarterly Revenue Growth
27.70%vs Biotechnology peers
Gross Profit (TTM)
-59.96MKRW-42.07K · vs all stocks (USD)
EBITDA (TTM)
-8.66BKRW-6.08M · vs all stocks (USD)
Net Income (TTM)
-8.54BKRW-6.00M · vs all stocks (USD)
Operating Cash Flow (TTM)
-6.51BKRW-4.57M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-7.04BKRW-4.94M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
1.95BKRWFY2025 · Dec 31, 2025Cost of Goods Sold
1.86BKRWFY2025 · Dec 31, 2025Gross Profit
88.63MKRWFY2025 · Dec 31, 2025Operating Income
-8.24BKRW-5.78M · vs all stocks (USD)
Pre-tax Income
-7.57BKRWFY2025 · Dec 31, 2025Net Income
-7.57BKRWFY2025 · Dec 31, 2025EBIT
-7.44BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
-6.66BKRWFY2025 · Dec 31, 2025Research & Development
4.97BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
591.25MKRWFY2025 · Dec 31, 2025Other Operating Expenses
141.55MKRWFY2025 · Dec 31, 2025Non-operating Interest Income
813.93MKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
137.03MKRWFY2025 · Dec 31, 2025Net Income from Continuing Operations
-7.57BKRWFY2025 · Dec 31, 2025Operating Cash Flow
-7.76BKRWFY2025 · Dec 31, 2025Free Cash Flow
-9.24BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.97BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-7.57BKRWFY2025 · Dec 31, 2025Stock-based Compensation
525.41MKRWFY2025 · Dec 31, 2025Other Non-cash Items
-1.27BKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-85.44MKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
640.96MKRWFY2025 · Dec 31, 2025Capital Expenditures
-1.47BKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-207.19MKRWFY2025 · Dec 31, 2025Purchase of Investments
-40.14BKRWFY2025 · Dec 31, 2025Sale of Investments
48.45BKRWFY2025 · Dec 31, 2025Other Investing Activity
-124.19MKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
6.71BKRWFY2025 · Dec 31, 2025Other Financing Charges
23.86MKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
316.23MKRWFY2025 · Dec 31, 2025Shares Outstanding
12.83MSharesUpdated Jul 15, 2026Float Shares
8.18MSharesUpdated Jul 15, 2026% Held by Insiders
38.14%vs all stocks
% Held by Institutions
0.39%vs all stocks
Total Cash (MRQ)
20.24BKRW14.20M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.58KKRWUpdated Jul 15, 2026Total Debt (MRQ)
8.33BKRW5.84M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.4048xvs Biotechnology peers
Current Ratio (MRQ)
11.95xvs Biotechnology peers
Book Value per Share (MRQ)
1.60KKRWUpdated Jul 15, 2026Total Assets
35.19BKRW24.69M · vs all stocks (USD)
Total Current Assets
25.10BKRWFY2025 · Dec 31, 2025Total Liabilities
12.41BKRWFY2025 · Dec 31, 2025Total Non-current Assets
10.09BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
10.15BKRWFY2025 · Dec 31, 2025Total Current Liabilities
2.26BKRWFY2025 · Dec 31, 2025Cash
306.00KKRWFY2025 · Dec 31, 2025Cash Equivalents
1.96BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.96BKRWFY2025 · Dec 31, 2025Other Short-term Investments
21.94BKRWFY2025 · Dec 31, 2025Accounts Receivable
195.22MKRWFY2025 · Dec 31, 2025Inventory
358.84MKRWFY2025 · Dec 31, 2025Accounts Payable
178.04MKRWFY2025 · Dec 31, 2025Short-term Debt
1.09BKRWFY2025 · Dec 31, 2025Other Current Liabilities
80.00KRWFY2025 · Dec 31, 2025Long-term Debt
7.33BKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
560.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
6.42BKRWFY2025 · Dec 31, 2025Retained Earnings
-51.18BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
22.79BKRW15.99M · vs all stocks (USD)
52-Week Low
12.26KKRWUpdated Jul 15, 202652-Week High
42.20KKRWUpdated Jul 15, 202652-Week Change
-46.47%vs all stocks
50-Day MA
21.40KKRWUpdated Jul 15, 2026200-Day MA
23.96KKRWUpdated Jul 15, 2026Avg 10-Day Volume
27.46KSharesUpdated Jul 15, 2026Avg 30-Day Volume
40.15KSharesUpdated Jul 15, 2026Diluted EPS (TTM)
-591.00KRWUpdated Jul 15, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is -0.1%, lower than 95% of its Biotechnology peers (median 67.1%)Significant
Gross margin: -0.00Industry median: 0.67Industry P5: 0.14Peers compared: 261
Financial Health
Altman Z-Score 6.47: safe zoneNotable
Altman Z-Score: 6.47
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $121.46M, lower than 95% of all stocks globallySignificant
Market cap (USD): 121,455,290.066Global P5: 269,387,740.27
Revenue is $1.46M, lower than 95% of all stocks globallySignificant
Revenue (USD): 1,458,063.67Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
PepGen Inc.
Tier 1ProductionApproval-Gated PipelineRule
3Billion Inc.
Tier 1ProductionApproval-Gated PipelineSenseMakingRule
Nibec Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Polaryx Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Engene Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRule
CVRx, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Faron Pharmaceuticals Oy
Tier 1ProductionApproval-Gated PipelineRuleRisk
Pyridam Farma Tbk.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Y-Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Curacle Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking